Home › Sjogren's Syndrome › Florida › Tampa
Sjogren's Syndrome clinical trials in Tampa, FL
4 studies for Sjogren's Syndrome are looking for participants at sites in and around Tampa (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
RecruitingPhase 3
- Clinical Research of West Florida Inc, Tampa
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
RecruitingPhase 2
- Clinical Research of West Florida Inc, Tampa
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
RecruitingPhase 3
- Finlay Medical Research Corp, Green Acres · 15 mi away
A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
RecruitingPhase 3
- BayCare Medical Group Primary Care and Rheumatology - Tampa, Tampa
About Sjogren's Syndrome
Sjogren's Syndrome is an autoimmune disease that causes dryness of the mouth, eyes and other parts of the body. Learn how to relieve the symptoms.
More about Sjogren's Syndrome on MedlinePlus
Sjogren's Syndrome trials in other cities
- Houston, TX6 studies
- Boston, MA5 studies
- Washington, DC5 studies
- Arlington, TX4 studies
- Charlotte, NC4 studies
- Cicero, IL4 studies
- Clearwater, FL3 studies
- Kansas City, MO3 studies
- Tucson, AZ3 studies
- Cypress, TX3 studies
- Warren, MI3 studies
- Orlando, FL3 studies
Other studies in Tampa
- Non-Small Cell Lung Cancer51 studies
- Breast Cancer43 studies
- Cancer (all types)39 studies
- Colorectal Cancer34 studies
- Acute Myeloid Leukemia29 studies
- Metastatic Cancer29 studies
- Lung Cancer29 studies
- Pancreatic Cancer26 studies
- Ovarian Cancer21 studies
- Melanoma19 studies
- Myelodysplastic Syndromes19 studies
- Prostate Cancer18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.